Artelo Historical Financial Ratios
| ARTL Stock | USD 1.05 0.08 8.25% |
Artelo Biosciences is presently reporting on over 106 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.46 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Artelo Biosciences financial condition quickly.
Artelo |
About Artelo Financial Ratios Analysis
Artelo BiosciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Artelo Biosciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Artelo financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Artelo Biosciences history.
Artelo Biosciences Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Artelo Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Artelo Biosciences sales, a figure that is much harder to manipulate than other Artelo Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Return On Tangible Assets
A profitability metric that measures a company's ability to generate earnings from its tangible assets.Most ratios from Artelo Biosciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Artelo Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.At this time, Artelo Biosciences' Graham Number is quite stable compared to the past year. Shareholders Equity Per Share is expected to rise to 6.82 this year, although the value of Free Cash Flow Yield is projected to rise to (1.07).
| 2019 | 2020 | 2021 | 2023 (projected) | Net Debt To EBITDA | 0.45 | 0.88 | 0.66 | 0.76 | Intangibles To Total Assets | 0.47 | 0.16 | 0.0998 | 0.11 |
Artelo Biosciences fundamentals Correlations
Click cells to compare fundamentals
Artelo Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Artelo Biosciences fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 0.77 | 0.92 | 1.41 | 0.42 | 0.49 | 0.46 | |
| Book Value Per Share | 37.93 | 15.69 | 9.67 | 6.85 | 6.17 | 6.82 | |
| Free Cash Flow Yield | (1.02) | (1.22) | (0.36) | (0.98) | (1.13) | (1.07) | |
| Operating Cash Flow Per Share | (19.39) | (17.6) | (4.93) | (2.83) | (3.25) | (3.41) | |
| Pb Ratio | 0.77 | 0.92 | 1.41 | 0.42 | 0.49 | 0.46 | |
| Free Cash Flow Per Share | (29.82) | (17.6) | (4.93) | (2.83) | (3.25) | (3.41) | |
| Roic | (0.0348) | (1.19) | (0.61) | (0.52) | (0.6) | (0.57) | |
| Net Income Per Share | (15.08) | (18.85) | (5.97) | (3.49) | (4.01) | (4.21) | |
| Cash Per Share | 30.72 | 8.67 | 8.08 | 6.19 | 5.57 | 5.92 | |
| Pocfratio | (1.51) | (0.82) | (2.77) | (1.02) | (0.92) | (0.97) | |
| Pfcf Ratio | (0.98) | (0.82) | (2.77) | (1.02) | (0.92) | (0.97) | |
| Income Quality | 1.29 | 0.93 | 0.83 | 0.79 | 0.71 | 0.7 | |
| Roe | (0.4) | (1.2) | (0.62) | (0.51) | (0.59) | (0.56) | |
| Ev To Operating Cash Flow | 0.0759 | (0.33) | (1.71) | (0.17) | (0.15) | (0.16) | |
| Pe Ratio | (1.94) | (0.76) | (2.29) | (0.83) | (0.75) | (0.78) | |
| Return On Tangible Assets | (0.49) | (1.99) | (0.7) | (0.54) | (0.48) | (0.51) | |
| Ev To Free Cash Flow | 0.0494 | (0.33) | (1.71) | (0.17) | (0.15) | (0.16) | |
| Earnings Yield | (0.52) | (1.31) | (0.44) | (1.21) | (1.39) | (1.32) | |
| Net Debt To E B I T D A | 0.14 | 1.05 | 0.45 | 0.88 | 0.66 | 0.76 | |
| Current Ratio | 4.35 | 4.65 | 19.61 | 18.36 | 16.52 | 17.35 | |
| Tangible Book Value Per Share | 23.76 | 7.43 | 8.03 | 6.13 | 5.52 | 4.62 | |
| Graham Number | 113.45 | 81.56 | 36.06 | 23.18 | 20.87 | 28.01 | |
| Shareholders Equity Per Share | 37.93 | 15.69 | 9.67 | 6.85 | 6.17 | 6.82 | |
| Graham Net Net | 23.64 | 6.64 | 7.61 | 5.83 | 5.25 | 4.42 | |
| Enterprise Value Over E B I T D A | (2.36) | 0.0503 | (0.3) | (1.41) | (0.13) | (0.12) | |
| Price Earnings Ratio | (1.94) | (0.76) | (2.29) | (0.83) | (0.75) | (0.78) | |
| Price Book Value Ratio | 0.77 | 0.92 | 1.41 | 0.42 | 0.49 | 0.46 | |
| Price Earnings To Growth Ratio | 0.0426 | (0.0299) | 0.0335 | 0.02 | 0.0229 | 0.0218 | |
| Price To Operating Cash Flows Ratio | (1.51) | (0.82) | (2.77) | (1.02) | (0.92) | (0.97) | |
| Price To Free Cash Flows Ratio | (0.98) | (0.82) | (2.77) | (1.02) | (0.92) | (0.97) | |
| Effective Tax Rate | 0.94 | 0.013 | 5.38E-4 | 0.0207 | 0.0238 | 0.0226 | |
| Return On Capital Employed | 17.36 | (0.59) | (1.21) | (0.61) | (0.53) | (0.58) | |
| Quick Ratio | 4.36 | 4.65 | 19.61 | 18.36 | 16.52 | 17.35 | |
| Cash Ratio | 4.33 | 4.27 | 12.6 | 6.9 | 7.94 | 8.0 | |
| Price To Book Ratio | 0.77 | 0.92 | 1.41 | 0.42 | 0.49 | 0.46 | |
| Price Cash Flow Ratio | (1.51) | (0.82) | (2.77) | (1.02) | (0.92) | (0.97) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Return On Assets (0.54) | Return On Equity (0.89) |
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.